Arbutus Biopharma Corp Files 8-K Report
Ticker: ABUS · Form: 8-K · Filed: Mar 3, 2025 · CIK: 1447028
| Field | Detail |
|---|---|
| Company | Arbutus Biopharma Corp (ABUS) |
| Form Type | 8-K |
| Filed Date | Mar 3, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: material-definitive-agreement, corporate-filing
TL;DR
Arbutus Biopharma filed an 8-K on March 3, 2025, reporting a material definitive agreement and other events.
AI Summary
On March 3, 2025, Arbutus Biopharma Corporation filed an 8-K report detailing a material definitive agreement. The filing also includes other events and financial statements/exhibits. Arbutus Biopharma Corporation was formerly known as Tekmira Pharmaceuticals Corp.
Why It Matters
This filing indicates significant corporate activity and potential changes for Arbutus Biopharma, requiring investor attention to understand the implications of the material definitive agreement and other reported events.
Risk Assessment
Risk Level: medium — The filing of an 8-K, especially one involving a material definitive agreement, can signal significant corporate developments that may impact the company's stock price and future prospects.
Key Players & Entities
- Arbutus Biopharma Corporation (company) — Registrant
- Tekmira Pharmaceuticals Corp (company) — Former company name
- March 3, 2025 (date) — Date of report
FAQ
What is the nature of the material definitive agreement reported by Arbutus Biopharma Corporation?
The filing does not specify the details of the material definitive agreement, only that one has been entered into.
When was the 8-K report filed by Arbutus Biopharma Corporation?
The 8-K report was filed on March 3, 2025.
What was Arbutus Biopharma Corporation's former name?
Arbutus Biopharma Corporation was formerly known as Tekmira Pharmaceuticals Corp.
What is the principal executive office address for Arbutus Biopharma Corporation?
The principal executive office is located at 701 Veterans Circle, Warminster, Pennsylvania 18974.
Under which section of the Securities Exchange Act is this 8-K report filed?
This 8-K report is filed pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on March 3, 2025 regarding Arbutus Biopharma Corp (ABUS).